# Cingulate Inc.: overview CING · Nasdaq · CIK 1862150 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cing.md) · [Financials](/companies/cing/financials.md) · [Filings](/companies/cing/filings.md) · [Insiders](/companies/cing/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.34)](/filings/0001493152-25-022395.md) | not reported | [(1.06)](/filings/0001493152-26-022884.md) | [(1.14)](/filings/0001493152-26-037606.md) | [(1.35)](/filings/0001493152-25-022395.md) | not reported | [(0.95)](/filings/0001493152-26-022884.md) | [(0.45)](/filings/0001493152-26-037606.md) | | Free cash flow | $k | [(4,024) d](/filings/0001493152-25-022395.md) | [(4,278) d](/filings/0001493152-26-010882.md) | not reported | not reported | [(4,244) d](/filings/0001493152-25-022395.md) | [(3,754) d](/filings/0001493152-26-010882.md) | [(6,974)](/filings/0001493152-26-022884.md) | [(5,967) d](/filings/0001493152-26-037606.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.79)](/filings/0001493152-22-007903.md) | [(29.35)](/filings/0001493152-24-012159.md) | [(311.99)](/filings/0001641172-25-000970.md) | [(10.86)](/filings/0001493152-26-010882.md) | [(4.44)](/filings/0001493152-26-010882.md) | | Free cash flow | $m | [(11.2)](/filings/0001493152-23-007252.md) | [(16.0)](/filings/0001493152-24-012159.md) | [(15.3)](/filings/0001641172-25-000970.md) | [(18.7)](/filings/0001493152-26-010882.md) | [(17.4)](/filings/0001493152-26-010882.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cing/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.1m | 570,873 | | Added +261,906 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.2m | 218,600 | Put | New +218,600 | | [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $912.9k | 166,898 | | New +166,898 | | [Chicago Partners Investment Group LLC](/funds/1563525.md) | 2026-06-30 | $912.0k | 188,429 | | Added +169,679 | | [Kestra Advisory Services, LLC](/funds/1830819.md) | 2026-06-30 | $828.7k | 151,500 | | Added +11,500 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $791.4k | 144,636 | | Added +43,263 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $778.4k | 142,300 | Call | New +142,300 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $697.4k | 127,500 | | Added +95,612 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $433.0k | 79,160 | | Added +29,086 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $294.3k | 53,800 | Call | New +53,800 | ## Recent filings [All 493 filings](/companies/cing/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 20:30 ET | [8-K](/filings/0001493152-26-045527.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-045527 | | 2026-08-13 | 12:45 ET | [10-Q](/filings/0001493152-26-037606.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037606 | | 2026-08-13 | 12:40 ET | [8-K](/filings/0001493152-26-037605.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037605 | | 2026-07-23 | 20:05 ET | [8-K](/filings/0001493152-26-034402.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-034402 | | 2026-07-14 | 12:00 ET | [8-K](/filings/0001493152-26-033115.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-033115 | | 2026-07-02 | 12:40 ET | [8-K](/filings/0001493152-26-031668.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-031668 | | 2026-06-16 | 12:10 ET | [8-K](/filings/0001493152-26-028815.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028815 | | 2026-06-02 | 12:10 ET | [8-K](/filings/0001493152-26-026760.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-026760 | | 2026-05-29 | 13:16 ET | [DEF 14A](/filings/0001493152-26-025721.md) | Proxy statement, period 2026-05-29 | 0001493152-26-025721 | | 2026-05-19 | 20:50 ET | [8-K](/filings/0001493152-26-024435.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-024435 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010882.md), filed Mar 18, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1862150 - Tickers: CING, CINGW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.